Log In
BCIQ
Print this Print this
 

Zinplava, bezlotoxumab (MK-6072) (formerly CDB-1, MDX-1388)

Also known as: formerly MBL-CDB1

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb targeting Clostridium difficile toxin B (TcdB)
Molecular Target Clostridium difficile toxin B (TcdB)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$225.0M

$60.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/27/2009

$225.0M

$60.0M

Undisclosed

Get a free BioCentury trial today